drugset
drugset / Trial / NCT02953873

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

NCT02953873 ↗

Phase 4 Completed 25 enrolled Medical University of South Carolina Astellas Pharma Inc · collab
NaSingle-groupOpen-labelTreatment

Summary

Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.

Timeline

Start
2017-05-05
Primary completion
2018-09-10
Completion
2018-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Extended Release Capsule Unknown — —
Background Mycophenolate Mofetil Small molecule 500 mg —
Background Mycophenolate Sodium Unknown 360 mg —
Background Prednisone Other / unclassified 5 mg —

Indications

immunodeficiency disease